1. Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH. White paper: Developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. J Infect Dis. 2017;216:228–36.
2. Bulik CC, Bhavnani SM, Hammel JP, Forrest A, Dudley MN, Ellis-Grosse EJ, Drusano GL, Ambrose PG. Evaluation of the probability of regulatory approval based on pre-clinical pharmacokinetic-pharmacodynamic target attainment for community-acquired bacterial and hospital-acquired bacterial pneumonia. In: Abstracts of the Interscience conference on antimicrobial agents and chemotherapy, Denver, September 10–13, 2013. Abstract A-295.
3. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis. 2007;44:79–86.
4. Ambrose PG. Antibacterial drug development program successes and failures: a pharmacometric explanation. Curr Opin Pharmacol. 2017;36:1–7.
5. United States Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. October 2013.